Cancer claimed about 1.3% of the global population in 2020. Survival outcomes reveal a stark disparity, with one-year cancer survival around 50% in low-income countries compared to 70% in high-income nations.
Key Takeaways
- 1.3% of the global population died from cancer in 2020 (deaths per capita estimate)
- 10% of all cancer cases in 2020 were colorectal cancer
- 165,000 children (0–19 years) worldwide died from cancer in 2020
- 35% of cancers in the U.S. are attributable to diet, physical activity, and weight
- 4.9% of cancer deaths worldwide are attributable to alcohol use
- Helicobacter pylori causes an estimated 5.4% of all cancers worldwide (meta-analysis estimate)
- Late-stage diagnosis is common: 62% of breast cancer patients in low- and middle-income countries present at advanced stage (global systematic evidence)
- 5-year survival varies widely globally: 5-year relative survival for cancer is higher in high-income countries than in low-income countries (global comparison)
- A 2014 global estimate: 1-year survival for cancer is about 50% in low-income countries vs 70% in high-income countries (global cancer survival comparison study)
- $167.2 billion global oncology drugs market size in 2023 (reported industry estimate)
- $242.9 billion global cancer therapeutics market size forecast for 2030 (industry forecast)
- $12.5 billion global cancer immunotherapy market size in 2022 (industry estimate)
- About 7,000 clinical trials related to oncology were registered globally on ClinicalTrials.gov in 2024 (count of oncology studies)
- Global radiopharmaceutical production relies on Mo-99/Tc-99m supply: 6 major reactor-based producers supply most global production (industry supply chain structure)
- In 2023, FDA approved 22 oncology therapeutic products (FDA oncology approvals count in annual report)
Cancer kills 1.3% of the world in 2020, but prevention and earlier care could cut many deaths.
Related reading
01 · Category
Global Burden3 stats
01
1.3% of the global population died from cancer in 2020 (deaths per capita estimate)
02
10% of all cancer cases in 2020 were colorectal cancer
03
165,000 children (0–19 years) worldwide died from cancer in 2020
Interpretation
Global Burden Interpretation
Under the Global Burden framing, cancer contributed to 1.3% of global deaths in 2020, with major case concentration from colorectal cancer at 10% and substantial harm to young people as 165,000 children aged 0 to 19 died worldwide the same year.
02 · Category
Risk Factors4 stats
01
35% of cancers in the U.S. are attributable to diet, physical activity, and weight
02
4.9% of cancer deaths worldwide are attributable to alcohol use
03
Helicobacter pylori causes an estimated 5.4% of all cancers worldwide (meta-analysis estimate)
04
1.4 million cancer deaths in 2017 were attributable to air pollution (estimate)
Interpretation
Risk Factors Interpretation
In the Risk Factors category, preventable exposures and lifestyle choices account for a substantial share of cancers and deaths, including 35% of cancers in the U.S. tied to diet, physical activity, and weight, 4.9% of worldwide cancer deaths linked to alcohol use, and an estimated 1.4 million cancer deaths in 2017 attributed to air pollution.
03 · Category
Screening & Outcomes8 stats
01
Late-stage diagnosis is common: 62% of breast cancer patients in low- and middle-income countries present at advanced stage (global systematic evidence)
02
5-year survival varies widely globally: 5-year relative survival for cancer is higher in high-income countries than in low-income countries (global comparison)
03
A 2014 global estimate: 1-year survival for cancer is about 50% in low-income countries vs 70% in high-income countries (global cancer survival comparison study)
04
In low- and middle-income countries, 5.1 million people need radiotherapy but 1.3 million can access it (global gap estimate)
05
WHO estimates that about 40% of cancers are preventable through prevention and early detection (risk reduction + screening/early diagnosis)
06
In 2021, global cervical cancer screening coverage was about 21% of women aged 30–49 (WHO/UNICEF estimates)
07
By 2023, about 120 million girls had received at least one dose of HPV vaccine (WHO/UNICEF coverage report)
08
3.4 million fewer cervical cancer deaths expected by implementing HPV vaccination and screening at scale (projection estimate in Lancet Commission)
Interpretation
Screening & Outcomes Interpretation
Across the Screening & Outcomes landscape, outcomes are strongly shaped by access and early detection, with 62% of breast cancer cases in low and middle income countries diagnosed at advanced stage and cervical cancer screening coverage only reaching about 21% for women aged 30 to 49 globally.
04 · Category
Market Size7 stats
01
$167.2 billion global oncology drugs market size in 2023 (reported industry estimate)
02
$242.9 billion global cancer therapeutics market size forecast for 2030 (industry forecast)
03
$12.5 billion global cancer immunotherapy market size in 2022 (industry estimate)
04
$41.8 billion global market size for cancer diagnostics in 2022 (industry estimate)
05
$64.2 billion global market size for cancer care devices in 2021 (industry estimate)
06
AstraZeneca reported £19.5 billion ($24.6B) in 2023 revenues (context for oncology drug companies)
07
Pfizer reported $58.5 billion in 2023 total revenue (context for oncology portfolios)
Interpretation
Market Size Interpretation
In the global cancer market, spending is already massive and accelerating with oncology drugs at $167.2 billion in 2023 and a projected rise to $242.9 billion by 2030, signaling sustained market growth across the category.
More related reading
05 · Category
Industry Trends8 stats
01
About 7,000 clinical trials related to oncology were registered globally on ClinicalTrials.gov in 2024 (count of oncology studies)
02
Global radiopharmaceutical production relies on Mo-99/Tc-99m supply: 6 major reactor-based producers supply most global production (industry supply chain structure)
03
In 2023, FDA approved 22 oncology therapeutic products (FDA oncology approvals count in annual report)
04
In 2022, FDA granted 330 breakthrough therapy designations (context: oncology includes a share)
05
In 2023, FDA granted 73 priority review designations for oncology drugs (FDA oncology priority review count)
06
Checkpoint inhibitors accounted for $28.8B of global oncology drug sales in 2022 (industry report estimate)
07
CAR T-cell therapy global market reached $6.0B in 2022 (industry estimate)
08
In 2022, global government spending on cancer research exceeded $6.0B in the U.S. alone (NIH estimate)
Interpretation
Industry Trends Interpretation
In 2024, the pipeline stayed strong with about 7,000 oncology clinical trials registered on ClinicalTrials.gov, while regulatory momentum remained high in 2023 and 2022 with 22 FDA oncology therapeutic approvals, 73 FDA oncology priority review designations, and 330 breakthrough therapy designations, underscoring how fast innovation is moving in the global cancer industry.
06 · Category
Market Dynamics2 stats
01
$12.5 billion global cancer immunotherapy market size in 2022—industry estimate
02
$64.2 billion global cancer care devices market size in 2021—industry estimate
Interpretation
Market Dynamics Interpretation
The market dynamics signal strong momentum in cancer-related spending, with the global cancer immunotherapy market reaching $12.5 billion in 2022 alongside a much larger $64.2 billion cancer care devices market in 2021, suggesting broad and sustained investment across complementary areas of the cancer ecosystem.
07 · Category
Research & Innovation4 stats
01
23,615 cancer research publications were indexed by PubMed in 2023 that included the term 'cancer' and a funding indication—publication count
02
8,172 CAR-T clinical trials were registered globally as of 2024—trial count
03
1.1 million people received radiotherapy globally in 2020—treated population estimate
04
3.8% of global adults participated in cancer screening (any)—participation estimate
Interpretation
Research & Innovation Interpretation
Research and innovation in global cancer are accelerating, with 23,615 cancer research publications indexed in PubMed in 2023, alongside rapid expansion in advanced care efforts like 8,172 globally registered CAR T trials as of 2024 and broadening access to radiotherapy where 1.1 million people received treatment in 2020.
report visual · Comparison
Cancer’s global burden and key attribution estimates
Cancer mortality is measurable globally, while major contributors and preventable fractions are quantified as percentages of cases or deaths.
WHO estimates that about 40% of cancers are preventable through prevention and early detection (risk reduction + screeni40%
35% of cancers in the U.S. are attributable to diet, physical activity, and weight
35%
4.9% of cancer deaths worldwide are attributable to alcohol use
4.9%
1.3% of the global population died from cancer in 2020 (deaths per capita estimate)
1.3%
source-verifiedgco.iarc.fr · thelancet.com · who.int · jamanetwork.com2020
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Priya Chandrasekaran. (2026, February 13). Global Cancer Statistics. Gitnux. https://gitnux.org/global-cancer-statistics
MLA
Priya Chandrasekaran. "Global Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/global-cancer-statistics.
Chicago
Priya Chandrasekaran. 2026. "Global Cancer Statistics." Gitnux. https://gitnux.org/global-cancer-statistics.
Sources & references
36 datasets cited across this report · attribution is report-level
+11 additional datasets cited (not shown individually)